AR117219A1 - Formulaciones en cápsulas, método de preparación - Google Patents
Formulaciones en cápsulas, método de preparaciónInfo
- Publication number
- AR117219A1 AR117219A1 ARP190103505A ARP190103505A AR117219A1 AR 117219 A1 AR117219 A1 AR 117219A1 AR P190103505 A ARP190103505 A AR P190103505A AR P190103505 A ARP190103505 A AR P190103505A AR 117219 A1 AR117219 A1 AR 117219A1
- Authority
- AR
- Argentina
- Prior art keywords
- compound
- formula
- solid solution
- solution capsule
- capsules
- Prior art date
Links
- 239000002775 capsule Substances 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 5
- 239000006104 solid solution Substances 0.000 abstract 5
- 239000007963 capsule composition Substances 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 238000002844 melting Methods 0.000 abstract 2
- 230000008018 melting Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000002736 nonionic surfactant Substances 0.000 abstract 2
- 239000002904 solvent Substances 0.000 abstract 2
- 102000005590 Anaphylatoxin C5a Receptor Human genes 0.000 abstract 1
- 108010059426 Anaphylatoxin C5a Receptor Proteins 0.000 abstract 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 abstract 1
- SHBUUTHKGIVMJT-UHFFFAOYSA-N Hydroxystearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OO SHBUUTHKGIVMJT-UHFFFAOYSA-N 0.000 abstract 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000012458 free base Substances 0.000 abstract 1
- 229940072106 hydroxystearate Drugs 0.000 abstract 1
- 230000007935 neutral effect Effects 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4833—Encapsulating processes; Filling of capsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Inorganic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente provee formulaciones en cápsulas de solución sólida del Compuesto de fórmula (1) y métodos para preparar las mismas. En la presente también se proveen métodos para tratar individuos que padecen de, o son susceptibles a, una enfermedad o trastorno que implica la activación patológica de receptores de C5a al administrar una cantidad efectiva de una o más cápsulas de solución sólida que comprenden el Compuesto de fórmula (1). En la presente se proveen, además, cápsulas de dosis unitarias que comprenden ciertas cantidades del Compuesto de fórmula (1), y kits que comprenden una cápsula de solución sólida que comprende el Compuesto de fórmula (1). Reivindicación 1: Una formulación en cápsula de solución sólida que comprende el Compuesto de fórmula (1) como base libre, en su forma neutra o en forma de una sal farmacéuticamente aceptable y un vehículo que comprende al menos un agente tensioactivo no iónico que tiene un valor de equilibrio hidrófilo-lipófilo (HLB) de al menos 10, y al menos un solubilizante soluble en agua que tiene un punto de fusión igual o superior a 37ºC. Reivindicación 19: La cápsula de solución sólida de una cualquiera de las reivindicaciones 1 a 10, en donde dicho al menos un agente tensioactivo no iónico que tiene un valor de HLB de al menos 10 es macrogol-40-glicol hidroxiestearato y dicho al menos un solubilizante soluble en agua que tiene una temperatura de fusión igual o superior a 37ºC es PEG-4000.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862773848P | 2018-11-30 | 2018-11-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR117219A1 true AR117219A1 (es) | 2021-07-21 |
Family
ID=70849818
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP190103505A AR117219A1 (es) | 2018-11-30 | 2019-11-29 | Formulaciones en cápsulas, método de preparación |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US20200170957A1 (es) |
| EP (2) | EP3886820B8 (es) |
| JP (1) | JP7342124B2 (es) |
| KR (1) | KR102586747B1 (es) |
| CN (1) | CN113164403A (es) |
| AR (1) | AR117219A1 (es) |
| AU (1) | AU2019389031B2 (es) |
| BR (1) | BR112021010285A2 (es) |
| CA (1) | CA3120999A1 (es) |
| CL (1) | CL2021001389A1 (es) |
| CY (1) | CY1126079T1 (es) |
| DK (1) | DK3886820T3 (es) |
| ES (1) | ES2943492T3 (es) |
| FI (1) | FI3886820T3 (es) |
| HR (1) | HRP20230551T1 (es) |
| HU (1) | HUE062551T2 (es) |
| IL (1) | IL283450B1 (es) |
| LT (1) | LT3886820T (es) |
| MA (1) | MA54318B1 (es) |
| MD (1) | MD3886820T2 (es) |
| MX (1) | MX2021006242A (es) |
| PL (1) | PL3886820T3 (es) |
| PT (1) | PT3886820T (es) |
| RS (1) | RS64250B1 (es) |
| SG (1) | SG11202105572UA (es) |
| SI (1) | SI3886820T1 (es) |
| TW (1) | TWI827745B (es) |
| WO (1) | WO2020112961A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MD3886820T2 (ro) | 2018-11-30 | 2023-07-31 | Chemocentryx Inc | Formulări de capsule |
| WO2023225533A1 (en) * | 2022-05-19 | 2023-11-23 | Dow Global Technologies Llc | Use of peg-based interpolymer complexes for improved solubilization of bcs class ii drugs |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR038681A1 (es) | 2002-02-14 | 2005-01-26 | Solvay Pharm Bv | Formulacion oral de solucion solida de una sustancia activa pobremente soluble en agua |
| CN101065115A (zh) * | 2004-11-24 | 2007-10-31 | 默克公司 | 取代酰胺的液体和半固体口服药物制剂 |
| DE102005053066A1 (de) | 2005-11-04 | 2007-05-10 | Basf Ag | Verwendung von Copolymeren als Solubilisatoren für in Wasser schwerlöslichen Verbindungen |
| WO2010075257A1 (en) | 2008-12-22 | 2010-07-01 | Chemocentryx, Inc. | C5ar antagonists |
| WO2011112558A2 (en) * | 2010-03-10 | 2011-09-15 | Abbott Laboratories | Solid compositions |
| PL2585064T3 (pl) | 2010-06-24 | 2017-09-29 | Chemocentryx, Inc. | Antagoniści C5AR |
| US9034858B2 (en) | 2010-11-30 | 2015-05-19 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
| AU2015215000B2 (en) | 2014-02-05 | 2017-10-19 | Lek Pharmaceuticals D.D. | Solid pharmaceutical compositions of androgen receptor antagonists |
| ES2926828T3 (es) | 2014-09-29 | 2022-10-28 | Chemocentryx Inc | Procesos e intermedios en la preparación de antagonistas de C5aR |
| TWI791423B (zh) | 2016-01-14 | 2023-02-11 | 美商卡默森屈有限公司 | C3腎絲球病變之治療方法 |
| CN109310686B (zh) | 2016-04-04 | 2022-06-21 | 凯莫森特里克斯股份有限公司 | 可溶性C5aR拮抗剂 |
| US10376595B2 (en) | 2017-04-03 | 2019-08-13 | Inflarx Gmbh | Treatment of inflammatory diseases with inhibitors of C5a activity |
| WO2018184739A1 (en) | 2017-04-03 | 2018-10-11 | Inflarx Gmbh | Treatment of inflammatory diseases with inhibitors of c5a activity |
| US20190144389A1 (en) | 2017-10-30 | 2019-05-16 | Chemocentryx, Inc. | Deuterated compounds as immunomodulators |
| KR20200109297A (ko) | 2017-10-31 | 2020-09-22 | 케모센트릭스, 인크. | 소변 sCD163의 C5aR 억제제 감소 |
| US11191756B2 (en) | 2018-06-07 | 2021-12-07 | Chemocentryx, Inc. | Dosing and effect of C5a antagonist with ANCA-associated vasculitis |
| MD3886820T2 (ro) | 2018-11-30 | 2023-07-31 | Chemocentryx Inc | Formulări de capsule |
-
2019
- 2019-11-27 MD MDE20210972T patent/MD3886820T2/ro unknown
- 2019-11-27 SG SG11202105572UA patent/SG11202105572UA/en unknown
- 2019-11-27 JP JP2021531035A patent/JP7342124B2/ja active Active
- 2019-11-27 LT LTEPPCT/US2019/063547T patent/LT3886820T/lt unknown
- 2019-11-27 PT PT198898736T patent/PT3886820T/pt unknown
- 2019-11-27 AU AU2019389031A patent/AU2019389031B2/en active Active
- 2019-11-27 PL PL19889873.6T patent/PL3886820T3/pl unknown
- 2019-11-27 DK DK19889873.6T patent/DK3886820T3/da active
- 2019-11-27 SI SI201930524T patent/SI3886820T1/sl unknown
- 2019-11-27 CA CA3120999A patent/CA3120999A1/en active Pending
- 2019-11-27 HU HUE19889873A patent/HUE062551T2/hu unknown
- 2019-11-27 FI FIEP19889873.6T patent/FI3886820T3/fi active
- 2019-11-27 CN CN201980079276.4A patent/CN113164403A/zh active Pending
- 2019-11-27 EP EP19889873.6A patent/EP3886820B8/en active Active
- 2019-11-27 US US16/697,523 patent/US20200170957A1/en not_active Abandoned
- 2019-11-27 RS RS20230433A patent/RS64250B1/sr unknown
- 2019-11-27 ES ES19889873T patent/ES2943492T3/es active Active
- 2019-11-27 EP EP23160271.5A patent/EP4233850A3/en active Pending
- 2019-11-27 IL IL283450A patent/IL283450B1/en unknown
- 2019-11-27 HR HRP20230551TT patent/HRP20230551T1/hr unknown
- 2019-11-27 KR KR1020217019883A patent/KR102586747B1/ko active IP Right Grant
- 2019-11-27 MA MA54318A patent/MA54318B1/fr unknown
- 2019-11-27 WO PCT/US2019/063547 patent/WO2020112961A1/en active Application Filing
- 2019-11-27 BR BR112021010285-0A patent/BR112021010285A2/pt not_active Application Discontinuation
- 2019-11-27 MX MX2021006242A patent/MX2021006242A/es unknown
- 2019-11-29 TW TW108143799A patent/TWI827745B/zh active
- 2019-11-29 AR ARP190103505A patent/AR117219A1/es unknown
-
2021
- 2021-05-27 CL CL2021001389A patent/CL2021001389A1/es unknown
- 2021-12-08 US US17/545,878 patent/US11951214B2/en active Active
-
2023
- 2023-07-03 CY CY20231100309T patent/CY1126079T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20181093A1 (es) | Compuestos heterociclicos y usos de los mismos | |
| CL2017002792A1 (es) | Derivados de ciclohexano sustituido con amido | |
| AR108046A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue | |
| CL2020000747A1 (es) | Formulaciones de niraparib. | |
| AR117219A1 (es) | Formulaciones en cápsulas, método de preparación | |
| PH12019502150A1 (en) | Compounds and methods for the treatment of parasitic diseases | |
| CO2019004004A2 (es) | Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico | |
| MX2020003993A (es) | Derivados de bencimidazol y sus usos. | |
| CL2019001023A1 (es) | Derivados de naftiridinona y su uso en el tratamiento de la arritmia. | |
| MX2016012784A (es) | Composiciones farmaceuticas solidas que comprenden derivados de biopterina y usos de tales composiciones. | |
| DOP2019000299A (es) | Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias | |
| JP2015506922A5 (es) | ||
| BR112019005578A2 (pt) | compostos de indazol para uso em lesões no tendão e/ou ligamento | |
| PE20181450A1 (es) | Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer | |
| JOP20180071B1 (ar) | استخدام مشتقات أمينو ألكيل بنزوثيازبين | |
| PE20190347A1 (es) | Formulaciones inyectables fisiologicamente balanceadas de fosnetupitant | |
| PE20181333A1 (es) | Derivados de indano y su uso en terapias | |
| AR114216A1 (es) | Composiciones oftálmicas de compuestos de bencimidazol para uso único diario | |
| UY39466A (es) | Compuestos y composiciones para el tratamiento de la criptosporidiosis | |
| CO2018001531A2 (es) | Lisobactina para su uso en el tratamiento de la mastitis bovina | |
| CL2020000356A1 (es) | Composiciones farmacéuticas. | |
| AR121966A1 (es) | Composiciones sólidas que contienen amina, amina protonada o compuestos de amonio cuaternario | |
| AR110330A1 (es) | Uso de derivados de bencimidazol para escape ácido nocturno | |
| AR112704A1 (es) | Agentes farmacéuticos como inhibidores del rsv para utilizar en combinación | |
| AR110319A1 (es) | Composición para el tratamiento de la osteoartritis |